Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes plc Reports First Quarter 2025 Financial Results
07:00am, Thursday, 01'st May 2025
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectati
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
07:00am, Wednesday, 30'th Apr 2025
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Provider
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
11:05am, Thursday, 24'th Apr 2025
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes to Report First Quarter Financial Results on May 1, 2025
04:00pm, Thursday, 17'th Apr 2025
DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
04:00pm, Wednesday, 02'nd Apr 2025
DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
10:35am, Wednesday, 02'nd Apr 2025
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
07:00am, Tuesday, 01'st Apr 2025
DUBLIN , April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients'
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
01:46pm, Tuesday, 25'th Mar 2025
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
08:00am, Saturday, 22'nd Mar 2025
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points Wit
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?
12:36pm, Friday, 14'th Mar 2025
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 26'th Feb 2025
DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
05:08am, Tuesday, 25'th Feb 2025
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
12:01pm, Thursday, 13'th Feb 2025
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year.
Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript
02:40pm, Wednesday, 12'th Feb 2025
Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard
